

UNITED STATES PATENT APPLICATION

**MAXIMUM ATRIAL TRACKING RATE FOR CARDIAC RHYTHM
MANAGEMENT SYSTEM**

INVENTORS

Gerrard M. Carlson
of Champlin, Minnesota, U.S.A.

Julio C. Spinelli
of Shoreview, Minnesota, U.S.A.

Qingsheng Zhu
of Little Canada, Minnesota, U.S.A.

Attorney: Suneel Arora

Reg. No. 42,267
Schwegman, Lundberg, Woessner, & Kluth, P.A.
1600 TCF Tower
121 South Eighth Street
Minneapolis, Minnesota 55402
ATTORNEY DOCKET NO. 00279.329US1

10040287-101901

MAXIMUM ATRIAL TRACKING RATE FOR CARDIAC RHYTHM MANAGEMENT SYSTEM

Technical Field

This document relates generally to cardiac rhythm management systems
5 and particularly, but not by way of limitation, to such a system including an
operational mode in which pacing pulses are delivered at a rate that tracks a
sinoatrial rate up to an appropriate maximum atrial tracking rate value determined
by the system.

Background

When functioning properly, the human heart maintains its own intrinsic
rhythm based on physiologically-generated electrical impulses. It is capable of
pumping adequate blood throughout the body's circulatory system. Each complete
cycle of drawing blood into the heart and then expelling it is referred to as a cardiac
15 cycle.

However, some people have irregular or other abnormal cardiac rhythms,
referred to as cardiac arrhythmias. Such arrhythmias result in diminished blood
circulation. One mode of treating cardiac arrhythmias uses drug therapy. Drugs are
often effective at restoring normal heart rhythms. However, drug therapy is not
20 always effective for treating arrhythmias of certain patients. For such patients, an
alternative mode of treatment is needed. One such alternative mode of treatment
includes the use of a cardiac rhythm management system. Such systems are often
implanted in the patient and deliver therapy to the heart.

Cardiac rhythm management systems include, among other things,
25 pacemakers, also referred to as pacers. Pacers deliver timed sequences of low
energy electrical stimuli, called pace pulses, to the heart, such as via an intravascular
leadwire or catheter (referred to as a "lead") having one or more electrodes disposed
in or about the heart. Heart contractions are initiated in response to such pace pulses
(this is referred to as "capturing" the heart). By properly timing the delivery of pace

pulses, the heart can be induced to contract in proper rhythm, greatly improving its efficiency as a pump. Pacers are often used to treat patients with bradyarrhythmias, that is, hearts that beat too slowly, or irregularly. Such pacers coordinate atrial and ventricular contractions to improve pumping efficiency.

Cardiac rhythm management systems also include defibrillators that are
5 capable of delivering higher energy electrical stimuli to the heart. Such
defibrillators also include cardioverters, which synchronize the delivery of such
stimuli to portions of sensed intrinsic heart activity signals. Defibrillators are often
used to treat patients with tachyarrhythmias, that is, hearts that beat too quickly.
Such too-fast heart rhythms also cause diminished blood circulation because the
10 heart isn't allowed sufficient time to fill with blood before contracting to expel the
blood. Such pumping by the heart is inefficient. A defibrillator is capable of
delivering a high energy electrical stimulus that is sometimes referred to as a
defibrillation countershock, also referred to simply as a "shock." The countershock
interrupts the tachyarrhythmia, allowing the heart to reestablish a normal rhythm for
15 the efficient pumping of blood. In addition to pacers, cardiac rhythm management
systems also include, among other things, pacer/defibrillators that combine the
functions of pacers and defibrillators, drug delivery devices, and any other
implantable or external systems or devices for diagnosing or treating cardiac
arrhythmias.

20 One problem faced by cardiac rhythm management systems is determining
the rate at which pacing pulses are delivered to the heart. Some systems include one
or more operational modes referred to as atrial tracking modes. In an atrial tracking
mode, the system detects atrial heart contractions triggered by the heart's
"physiological pacemaker," referred to as the sinoatrial node. Based on the rate of
25 the detected heart contractions, the system determines the rate of pacing pulses
delivered to a ventricle. Such an atrial tracking mode is useful in a patient having a
functional sinoatrial node, but where the patient has an atrioventricular node that
fails to conduct physiological electrical impulses from the atrium to the ventricle.

Some cardiac rhythm management systems further include one or more rate-responsive atrial tracking modes. In a rate-responsive atrial tracking mode, the system adjusts the rate of ventricular pacing pulses based not only on the rate of atrial heart contractions, but also based on a physiologic sensor-indication of the patient's metabolic need for increased blood circulation. One example of such a

5 sensor is an accelerometer that detects the patient's activity for providing an indication of a need for a higher pacing rate. Another example is a ventilation/respiration sensor that detects the patient's breathing rate for providing an indication of a need for a higher pacing rate. In one implementation of a rate-responsive atrial tracking mode, the ventricular pacing rate is based on the detected

10 atrial heart rate unless the physiologic sensor indicates a need for an even higher ventricular pacing rate.

In both the atrial tracking mode and the rate-responsive atrial tracking mode, the system typically includes a maximum atrial tracking rate (MATR). The MATR imposes a limit beyond which the ventricular rate does not track the detected atrial

15 heart rate. The MATR limit prevents pacing the ventricle at a dangerously high rate during an atrial tachyarrhythmia. One example of a cardiac rhythm management device includes a MATR of 120 beats per minute (bpm) as a factory default value. The physician can adjust the MATR at the time that the cardiac rhythm management device is implanted in the patient. The present inventors have recognized that

20 without additional clinical data informing the physician of an appropriate MATR value for a particular patient, the physician typically must settle for programming the MATR to an overly conservative value that may be inappropriately low for the particular patient, thereby limiting the patient's ability to exercise or engage in activity at higher heart rates. Moreover, cardiac rhythm management devices

25 typically include a multitude of programmable parameters that can be adjusted by the physician at the time of implant, increasing the complexity and time required for the implant procedure. Accordingly, the present inventors have recognized that there is a need for a cardiac rhythm management system that automatically

determines an appropriate MATR value.

Summary

A cardiac rhythm management system includes an operational mode in which ventricular pacing pulses are delivered at a rate that tracks a sinoatrial rate up to an appropriate maximum atrial tracking rate (MATR) value determined by the system. In one example, the MATR value is based on a patient activity level and a hemodynamic maximum rate (HMR) determined from a QRS-to-S₂ interval, where S₂ is an accelerometer-generated fiducial correlative to aortic valve closure (AVC). In a further example, a correlation between the QRS-to-S₂ interval and heart rate is established, and the MATR is based on the patient activity level and heart rate. In a further example, a lower rate threshold for providing antitachyarrhythmia therapy is modified based on the MATR. For example, when the MATR exceeds a default value of the antitachyarrhythmia therapy lower rate threshold, the threshold tracks the MATR. In another example, the MATR value is based on an active time between the QRS complex and a subsequent maximum slope point on a heart impedance signal during the same cardiac cycle.

In one example, the system provides a method including measuring a subinterval of a patient's cardiac cycle correlative to a hemodynamic maximum rate indicator, and establishing a maximum atrial tracking rate based at least in part on the hemodynamic maximum rate indicator.

In another example, the system includes a ventricular sensing channel to detect a QRS complex during a cardiac cycle. An accelerometer is adapted to detect a fiducial of a heart acceleration signal correlative to an aortic valve closure occurring during the cardiac cycle after the QRS complex, and to detect a patient activity level. A controller is adapted for calculating a maximum atrial tracking rate based at least in part on the activity level and a time interval between the QRS complex and the fiducial.

Other aspects of the system will become apparent upon reading the following

detailed description of the invention, viewing the drawings that form a part thereof, and viewing the claims that, together with the scope of equivalents to which they are entitled, define the scope of the present invention.

Brief Description of the Drawings

5 In the drawings, which are not necessarily drawn to scale, like numerals describe substantially similar components throughout the several views. Like numerals having different letter suffixes represent different instances of substantially similar components. The drawings illustrate generally, by way of example, but not by way of limitation, various embodiments discussed in the present document.

10 Figure 1 is a schematic illustration of an example of portions of a cardiac rhythm management system and portions of an environment in which it is used.

Figure 2 is a flow chart illustrating an example of how a physiologically appropriate maximum atrial tracking rate (MATR) is calculated.

15 Figure 3 is a graph of data illustrating S2m (in beats per minute) vs. EPeak (in beats per minute), where $S2m = 60,000 / (\text{QRS-to-}S_2 \text{ interval})$, in milliseconds, and $E\text{Peak} = 60,000 / (\text{QRS-to-AVC interval})$, in milliseconds.

Figure 4 is a schematic illustration example of three rate zones corresponding to different antitachyarrhythmia therapies provided by a cardiac rhythm management device.

20

Detailed Description

In the following detailed description, reference is made to the accompanying drawings which form a part hereof, and in which is shown by way of illustration specific embodiments in which the invention may be practiced. These embodiments
25 are described in sufficient detail to enable those skilled in the art to practice the invention, and it is to be understood that the embodiments may be combined, or that other embodiments may be utilized and that structural, logical and electrical changes may be made without departing from the spirit and scope of the present invention.

The following detailed description is, therefore, not to be taken in a limiting sense, and the scope of the present invention is defined by the appended claims and their equivalents.

This document discusses, among other things, a cardiac rhythm management system including an operational mode in which pacing pulses are delivered at a rate that tracks a sinoatrial rate up to an appropriate maximum atrial tracking rate value determined by the system. The present methods and apparatuses will be described in applications involving implantable medical devices including, but not limited to, implantable cardiac rhythm management systems such as pacemakers, cardioverter/defibrillators, pacer/defibrillators, biventricular or other multi-site coordination devices (which coordinate the nature of the heart contraction and may, but need not affect the rate of heart contractions), and drug delivery systems. However, it is understood that the present methods and apparatuses may be employed in unimplanted devices, including, but not limited to, external pacemakers, cardioverter/defibrillators, pacer/defibrillators, biventricular or other multi-site coordination devices, monitors, programmers and recorders, whether such devices are used for providing a diagnostic, a therapy, or both a diagnostic and a therapy.

Figure 1 is a schematic illustration of an example of portions of a cardiac rhythm management system **100** and portions of an environment in which it is used. In this example, system **100** includes, among other things, a cardiac rhythm management device **102**, which is coupled by one or more leads, such as **104A-B** to heart **106**. Heart **106** includes at least four chambers: right atrium **106A**, right ventricle **106B**, left atrium **106C**, and left ventricle **106D**.

In this example, lead **104A** includes an electrode associated with right atrium **106A**, such as electrode **108** and/or electrode **110** for sensing atrial heart signals and/or providing atrial pacing pulses. An electrode is "associated" with a particular heart chamber by inserting it into that heart chamber, by inserting it into a portion of the heart's vasculature that is close to that heart chamber, by epicardially placing the

electrode outside that heart chamber, or by any other technique of configuring and situating an electrode for sensing signals and/or providing therapy with respect to that heart chamber. Lead **104B** includes an electrode, such as electrode **112** or **114**, such as for sensing ventricular heart signals and/or providing ventricular pacing pulses. In this example, lead **104B** also includes an electrode, such as electrode **116**
5 associated with a right atrium or superior vena cava (SVC), for providing a defibrillation shock in conjunction with electrode **114** or one or more other electrodes.

Device **102** may also include other electrodes, such as housing electrode **118** and/or header electrode **120**, which are useful for, among other things, unipolar
10 sensing of heart signals and/or unipolar delivery of contraction-evoking pacing stimulations or defibrillation shocks in conjunction with one or more of the electrodes **108**, **110**, **112**, **114**, and **116** associated with heart **106**. Alternatively, bipolar sensing and/or pacing and/or defibrillation may be used, such as bipolar atrial sensing and/or pacing between electrodes **108** and **110**, or bipolar ventricular
15 sensing and/or pacing between electrodes **112** and **114**.

Device **102** includes a sensing module for sensing heart activity signals. The sensing module includes an atrial sensing channel **122** and a ventricular sensing channel **124**, each of which is coupled to one or more of the electrodes for sensing electrical depolarizations, corresponding to heart chamber contractions. Such
20 electrical depolarizations of the heart tissue include atrial depolarizations, referred to as P-waves, and ventricular depolarizations, referred to as QRS complexes. A typical QRS complex is a rapid sequence of three signal excursions away from a baseline in sequentially switching polarity, with the first excursion referred to as a Q-wave, the second (typically the largest) excursion referred to as an R-wave, and
25 the third excursion referred to as the S-wave. In one example, detecting a QRS complex includes peak-detecting or level-detecting the R-wave portion of the QRS complex. A ventricular heart signal also includes ventricular repolarizations, referred to as T-waves, which occur after respective QRS complexes in preparation

for a subsequent ventricular contraction. This P-Q-R-S-T nomenclature is commonly used to refer to signals obtained from body surface electrocardiograph features; it is understood, however, that in this document, the same nomenclature also pertains to corresponding features of intracardiac electrograms.

In this example, device **102** includes an atrial therapy module **126**, coupled
5 to one or more electrodes for delivering an atrial pacing pulse to induce an atrial heart contraction. Moreover, device **102** also includes a ventricular therapy module **128**, coupled to one or more ventricular electrodes for delivering a ventricular pacing pulse to induce a ventricular heart contraction and/or a ventricular defibrillation shock to interrupt an episode of ventricular fibrillation detected by
10 ventricular sensing channel **124**.

Device **102** also includes an acceleration sensing channel **130**. Acceleration sensing channel **130** includes an accelerometer capable of sensing the patient's motion or activity as well as accelerations produced by the heart itself as it contracts and expands to pump blood through the patient's circulatory system. Such heart
15 accelerations include an "S₂ heart sound" or other fiducial associated with closure of the heart's aortic valve. One example of a suitable acceleration sensing channel **130** for detecting the S₂ heart sound associated with aortic valve closure (AVC) is discussed in Carlson et al. U.S. Patent No. 5,792,195, entitled "Acceleration Sensed Safe Upper Rate Envelope for Calculating the Hemodynamic Upper Rate Limit For
20 a Rate Adaptive Cardiac Rhythm Management Device," which is assigned to Cardiac Pacemakers, Inc., and incorporated by reference herein in its entirety. Acceleration sensing channel **130** includes bandpass frequency filtering for passing heart sounds, which are in a frequency range that is approximately between 10 Hz and 140 Hz, and patient activity, which is in a frequency range that is approximately
25 between 1 Hz and 10 Hz. Acceleration sensing channel **130** also includes integration or lowpass filtering circuits, such as for integrating a magnitude or squared acceleration signal over a short time period to obtain a smoothed signal representative of the energy of the acceleration signal in the patient activity

frequency band.

Device 102 also includes a controller 132 or other microsequencer capable of executing instructions. Controller 132 is coupled by bus 134 to atrial sensing channel 122, ventricular sensing channel 124, atrial therapy module 126, ventricular therapy module 128, and acceleration sensing channel 130. In one embodiment, 5 controller 132 is also coupled by bus 136 to telemetry transceiver 138, which is configured for wireless communication with a remote device, such as external programmer 140.

Among other things, controller 132 executes instructions for issuing triggering and other control signals to ventricular therapy module 128 to issue 10 ventricular pacing pulses to heart 106 for evoking responsive ventricular heart contractions. In one or more modes of operation, referred to as atrial tracking modes, the ventricular pacing pulses are each delivered in response to intrinsic atrial contractions detected by atrial sensing channel 122 after a time delay referred to as an AV delay. Therefore, in an atrial tracking mode, the paced ventricular heart rate 15 tracks the sensed intrinsic atrial heart rate, referred to as the sinoatrial rate, up to, but not beyond, a maximum atrial tracking rate (MATR). Controller 132 further includes an algorithm for calculating a physiologically appropriate value for the MATR, different from a base or default MATR stored in register 142. The calculated MATR is then stored in register 144.

20 Figure 2 is a flow chart illustrating an example of how a physiologically appropriate MATR is calculated by controller 132. At 200, a QRS complex associated with a ventricular heart contraction is detected. In this document, the term "QRS complex" refers to both the depolarization associated with a sensed ventricular heart contraction as well as the depolarization associated with a paced 25 ventricular heart contraction (sometimes referred to as an "evoked response."). Moreover, for a paced ventricular contraction, the "QRS complex" also includes any pacing pulse that triggered the evoked response. At 200, a sensed QRS complex is detected by ventricular sensing channel 124; a paced QRS complex is detected either

by sensing the pace or its evoked response using the ventricular sensing channel 124, or by the issuance of a control signal by controller 132 that triggers the pace evoking the resulting ventricular contraction. Subsequently, during the same cardiac cycle, at 202, a S₂ heart sound associated with the corresponding aortic valve closure (and deemed an indication or fiducial representative thereof) is sensed by acceleration sensing channel 130. At 204, a time interval between the QRS complex and the S₂ heart sound is measured, using a timer in controller 132. This QRS-to-S₂ time interval, which is a subinterval of the patient's cardiac cycle, is stored in a register. At 206, the QRS-to-S₂ time interval (in milliseconds) is converted into a rate (in beats per minute). The QRS-to-S₂ rate is equal to 60,000 divided by the QRS-to-S₂ time interval. At 208, a rate offset value is added to the QRS-to-S₂ rate to obtain a rate corresponding to the QRS-to-AVC (aortic valve closure) time interval. At 210, this QRS-to-AVC rate is deemed a desired hemodynamic maximum rate (HMR) indicator and stored in a register. At 212, the patient's then-existing activity level (AL) is detected using acceleration sensing channel 130. The AL is derived from the energy of the acceleration signal within the patient activity frequency band, as discussed above, with additional smoothing. At 214, if that present AL exceeds a maximum activity level (MAL) over a preceding predetermined longer time interval (e.g., several hours, 24 hours, several days, a week, etc.), then the present AL is stored as the MAL at 216. One example of methods and apparatuses for detecting patient activity over a period of time is discussed in Kadhiresan et al. U.S. Patent No. 6,135,970, entitled "Method and Apparatus for Assessing Patient Well-Being," which is assigned to Cardiac Pacemakers, Inc., and which is incorporated herein by reference in its entirety. At 218, if the present AL does not exceed the MAL, then a physiologically appropriate MATR is calculated as:

$$\text{Calculated MATR} = \text{Default MATR} + (\text{HMR} - \text{Default MATR}) \cdot (\text{AL}/\text{MAL})$$

The base or default MATR is programmed (e.g., by the factory or by the physician) to a particular value that is approximately between 100 beats per minute and 150

beats per minute, such as about 120 beats per minute. At 220, the calculated MATR is stored in a register.

During subsequent delivery of ventricular pacing pulses in an atrial tracking mode, the paced ventricular heart rate only tracks the sensed intrinsic atrial heart rate up to the calculated MATR. When the detected atrial rate exceeds the MATR, the
5 ventricular pacing pulses are limited in some fashion, such as, for example, by issuing one ventricular pace pulse for every two (or more) sensed atrial heart depolarizations. This effectively maintains the paced ventricular heart rate at a safe value at high sensed atrial heart rates. Moreover, because the calculated MATR is physiologically based on the HMR obtained from the particular patient, it allows
10 ventricular pacing (and coordination or cardiac resynchronization therapy for patients requiring such therapy) to track the atrial rate up to a higher value, for some patients, than the corresponding default MATR. For active patients, needing higher ventricular pacing rates during exercise, this may be a substantial benefit.

Figure 3 is a graph of data 300 illustrating S2m (in beats per minute) vs.
15 EPeak (in beats per minute), where $S2m = 60,000/(\text{QRS-to-}S_2 \text{ interval})$, in milliseconds, and $E\text{Peak} = 60,000/(\text{QRS-to-AVC interval})$, in milliseconds. Data 300 was obtained from a number of patients and at a number of different heart rates. As discussed above, the QRS-to-AVC interval is the time interval between a QRS complex and a subsequent Doppler ultrasound indicated aortic valve closure
20 occurring later during the same cardiac cycle. The QRS-to- S_2 interval is the corresponding time interval between that QRS complex and the subsequent accelerometer-indicated S_2 heart sound that is also associated with aortic valve closure. Data 300 illustrates a strong correlation ($R = 0.92$) between the rate associated with the accelerometer QRS-to- S_2 interval and the rate associated with
25 the Doppler-indicated QRS-to-AVC interval. Data 300 indicates that this relationship can be expressed as $S2m \text{ (bpm)} = 1.06 \cdot E\text{Peak (bpm)} + 20.7$. Therefore, by subtracting a constant value of 20.7 beats per minute from the rate corresponding to the QRS-to- S_2 interval, such as at 208 of Figure 2, an approximate value of the

rate corresponding to the QRS-to-AVC time interval is obtained. Since the slope of the above equation is close to one, no slope correction is required, however, in a further example, such a slope correction is also performed to obtain additional accuracy in translating from the QRS-to-S₂ interval rate to the QRS-to-AVC interval rate to obtain a representative HMR for determining the MATR.

- 5 In one example, the technique illustrated in Figure 2 for calculating a physiologically-based MATR is carried out around the time device 102 is implanted in the patient (after acquiring enough patient activity data to establish an MAL). Then, device 102 is placed in an atrial tracking mode that delivers ventricular pacing pulses at a rate that tracks the sensed atrial rate up to the calculated MATR. In
- 10 another example, the technique illustrated in Figure 2 is carried out occasionally or periodically (e.g., monthly, weekly, daily, hourly, etc.) to update the calculated MATR even after the time around which device 102 is implanted in the patient. In a further example, the technique illustrated in Figure 2 is carried out on a beat-by-beat basis to update the physiologically calculated MATR each cardiac cycle. In such an
- 15 example, averaging, lowpass filtering, or other smoothing could be carried out to limit the degree to which the physiologically calculated MATR fluctuates on a beat-by-beat basis.

- In another example, the technique illustrated in Figure 2 for calculating a physiologically-based MATR is carried out repeatedly in the patient over a range of
- 20 ventricular heart rates. In one such example, the patient is placed on a treadmill for exercise to raise the heart rate. After such treadmill exercise is stopped, the ventricular heart rate is measured as it slowly returns toward its resting value. At various values of the declining ventricular heart rate, the technique illustrated in 200 through 210 of Figure 2 is used to calculate the HMR corresponding to that heart
- 25 rate. These values are used to create a map of HMR vs. heart rate that is stored in memory in controller 132. Then, at a later time, the MATR is calculated (e.g., occasionally, periodically, or even on a beat-by-beat basis) by measuring the then-existing heart rate (e.g., ventricular heart rate), selecting a corresponding MATR

from the previously-created HMR vs. heart rate map, and then using the technique in 212 through 220 of Figure 2 to calculate the MATR.

Figures 1 - 3 illustrate, among other things, particular examples of using a hemodynamic maximum rate indicator to establish a maximum atrial tracking rate such as, for example, by using a time interval between a QRS complex and an aortic valve closure to derive a hemodynamic maximum rate indicator. Alternative techniques exist for deriving a hemodynamic maximum rate indicator. One suitable example of obtaining a hemodynamic maximum rate indicator is based on an "active time" measurement. The "active time" refers to a time between the onset of a heart contraction and the point where a line passing through two points on the fast filling segment of a heart impedance waveform reaches an impedance level corresponding to the end-diastole impedance of the preceding beat. Example methods and apparatuses for performing the "active time" technique are discussed in Spinelli U.S. Patent No. 5,235,976 entitled "Method and Apparatus for Managing and Monitoring Cardiac Rhythm Using Active Time As the Controlling Parameter," which is assigned to Cardiac Pacemakers, Inc., and which is incorporated herein by reference in its entirety. The "active time" technique provides an alternative hemodynamic maximum rate indicator, which is used to limit the maximum atrial tracking rate.

In a further example, the calculated MATR is used to modify the delivery of antitachyarrhythmia therapy (e.g., antitachyarrhythmic pacing therapy and/or defibrillation shocks) provided by device 102. For example, certain cardiac rhythm management systems provide tiered antitachyarrhythmia therapy, that is, different antitachyarrhythmia therapies are provided based on which one of a plurality of rate zones a sensed ventricular or other heart rate falls in when the tachyarrhythmia episode is occurring. One example of rate-zone-based tiered therapy is discussed in Krig et al. U.S. Patent No. 6,151,524, entitled "Apparatus and Method for Treating Ventricular Tachyarrhythmias," which is assigned to Cardiac Pacemakers, Inc., and which is incorporated herein by reference in its entirety.

Figure 4 is a schematic illustration example of three rate zones

corresponding to different antitachyarrhythmia therapies provided by cardiac rhythm management device 102. When a tachyarrhythmia is detected, if the heart rate exceeds a first rate threshold, HR_1 , but does not exceed a second rate threshold HR_2 , a first antitachyarrhythmia therapy is provided. When the tachyarrhythmia is detected, if the heart rate exceeds the second rate threshold HR_2 , but does not exceed a third rate threshold, HR_3 , a second antitachyarrhythmia therapy is provided. When the tachyarrhythmia is detected, if the heart rate exceeds the third rate threshold HR_3 , a third antitachyarrhythmia therapy is provided. The rate thresholds HR_1 , HR_2 , and HR_3 are typically programmable by the physician at the time the cardiac rhythm management device is implanted. In one embodiment, if the MATR calculated by device 102 exceeds one or more of the programmed rate thresholds, device 102 increases at least one of the rate thresholds, thereby moving the corresponding zone up to a higher threshold rate value. For example, if the MATR calculated by device 102 exceeds HR_1 , then device 102 moves HR_1 to a value that equals or exceeds the calculated MATR. Similarly, if the subsequently recalculated MATR later falls to a value that is lower than the HR_1 value programmed by the physician, then device 102 returns HR_1 to its programmed value. In this manner, the calculated MATR is used to adjust a rate zone threshold or other criteria for providing antitachyarrhythmia therapy.

It is to be understood that the above description is intended to be illustrative, and not restrictive. For example, the above-described embodiments may be used in combination with each other. Many other embodiments will be apparent to those of skill in the art upon reviewing the above description. The scope of the invention should, therefore, be determined with reference to the appended claims, along with the full scope of equivalents to which such claims are entitled. In the appended claims, the terms "including" and "in which" are used as the plain-English equivalents of the respective terms "comprising" and "wherein."